欧盟批准伊普森的Ojemda用于小儿低度质瘤. EU approves Ipsen's Ojemda for pediatric low-grade glioma.

伊普森制药公司宣布欧盟已批准Ojemda,标记其为儿童复发性或耐火性低度质瘤的首个向治疗. Ipsen Pharma announced that the European Union has approved Ojemda, marking it as the first targeted therapy for relapsed or refractory pediatric low-grade glioma. 本批准适用于不论BRAF的变更状态. This approval applies regardless of BRAF alteration status.